Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 December 2020Website:
http://www.synaptogen.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 23:57:01 GMTDividend
Analysts recommendations
Institutional Ownership
What type of business is Synaptogenix?
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
What sector is Synaptogenix in?
Synaptogenix is in the Healthcare sector
What industry is Synaptogenix in?
Synaptogenix is in the Biotechnology industry
What country is Synaptogenix from?
Synaptogenix is headquartered in United States
When did Synaptogenix go public?
Synaptogenix initial public offering (IPO) was on 08 December 2020
What is Synaptogenix website?
https://www.synaptogen.com
Is Synaptogenix in the S&P 500?
No, Synaptogenix is not included in the S&P 500 index
Is Synaptogenix in the NASDAQ 100?
No, Synaptogenix is not included in the NASDAQ 100 index
Is Synaptogenix in the Dow Jones?
No, Synaptogenix is not included in the Dow Jones index
When does Synaptogenix report earnings?
The next expected earnings date for Synaptogenix is 14 August 2024